

Francesco Giorgino

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1135594/publications.pdf>

Version: 2024-02-01

244
papers

11,996
citations

28190
55
h-index

35952
97
g-index

256
all docs

256
docs citations

256
times ranked

16036
citing authors

#	ARTICLE	IF	CITATIONS
1	Salt reduction and iodine intake in Italy. <i>Journal of Endocrinological Investigation</i> , 2022, 45, 883-885.	1.8	5
2	SGLT-2 inhibitors as cardio-renal protective agents. <i>Metabolism: Clinical and Experimental</i> , 2022, 127, 154937.	1.5	20
3	Metabolic disorders and gastroenteropancreatic-neuroendocrine tumors (GEP-NETS): How do they influence each other? An Italian Association of Medical Oncology (AIOM)/ Italian Association of Medical Diabetologists (AMD)/ Italian Society of Endocrinology (SIE)/ Italian Society of Pharmacology (SIF) multidisciplinary consensus position paper. <i>Critical Reviews in Oncology/Hematology</i> , 2022, 169, 103572.	2.0	12
4	GLP-1 Receptor Agonists for Cardiovascular Protection: A Matter of Time. <i>Diabetes Care</i> , 2022, 45, e30-e31.	4.3	5
5	Mini Review: Effect of GLP-1 Receptor Agonists and SGLT-2 Inhibitors on the Growth Hormone/IGF Axis. <i>Frontiers in Endocrinology</i> , 2022, 13, 846903.	1.5	8
6	Cardiovascular and Renal Effectiveness of GLP-1 Receptor Agonists vs. Other Glucose-Lowering Drugs in Type 2 Diabetes: A Systematic Review and Meta-Analysis of Real-World Studies. <i>Metabolites</i> , 2022, 12, 183.	1.3	31
7	Late Endocrine and Metabolic Sequelae and Long-Term Monitoring of Classical Hodgkin Lymphoma and Diffuse Large B-Cell Lymphoma Survivors: A Systematic Review by the Fondazione Italiana Linfomi. <i>Cancers</i> , 2022, 14, 1439.	1.7	6
8	Managing weight and glycaemic targets in people with type 2 diabetes—How far have we come?. <i>Endocrinology, Diabetes and Metabolism</i> , 2022, 5, e00330.	1.0	9
9	Report from the CVOT Summit 2021: new cardiovascular, renal, and glycemic outcomes. <i>Cardiovascular Diabetology</i> , 2022, 21, 50.	2.7	8
10	Concomitant iGlarLixi and Sodium-Glucose Co-transporter-2 Inhibitor Therapy in Adults with Type 2 Diabetes: LixiLan-G Trial and Real-World Evidence Results. <i>Diabetes Therapy</i> , 2022, 13, 205-215.	1.2	5
11	A telemedicine-based approach with real-time transmission of blood glucose data improves metabolic control in insulin-treated diabetes: the DIAMONDS randomized clinical trial. <i>Journal of Endocrinological Investigation</i> , 2022, 45, 1663-1671.	1.8	7
12	Adipose Tissue Secretion Pattern Influences β -Cell Wellness in the Transition from Obesity to Type 2 Diabetes. <i>International Journal of Molecular Sciences</i> , 2022, 23, 5522.	1.8	18
13	Updating obesity management strategies: an audit of Italian specialists. <i>Eating and Weight Disorders</i> , 2022, 27, 2653-2663.	1.2	1
14	Ladarixin, an inhibitor of the interleukin-6 receptors $CXCR1$ and $CXCR2$, in new-onset type 1 diabetes: A multicentre, randomized, double-blind, placebo-controlled trial. <i>Diabetes, Obesity and Metabolism</i> , 2022, 24, 1840-1849.	2.2	17
15	The p66Shc Protein Mediates Insulin Resistance and Secretory Dysfunction in Pancreatic β -Cells Under Lipotoxic Conditions. <i>Diabetes</i> , 2022, 71, 1763-1771.	0.3	6
16	The Real-World Observational Prospective Study of Health Outcomes with Dulaglutide & Liraglutide in Type 2 Diabetes Patients (TROPHIÉS): 12-month data analysis. <i>Diabetologie Und Stoffwechsel</i> , 2022, , .	0.0	0
17	Therapieintensivierung bei Typ-2-Diabetespatienten mit basalunterstützter oraler Therapie (BOT): Hypoglykämien als Funktion des HbA1c in der SoliMix-Studie. <i>Diabetologie Und Stoffwechsel</i> , 2022, , .	0.0	0
18	Adipose Tissue Inflammation and Pulmonary Dysfunction in Obesity. <i>International Journal of Molecular Sciences</i> , 2022, 23, 7349.	1.8	26

#	ARTICLE	IF	CITATIONS
19	Reduction of hypoglycaemia, lifestyle modifications and psychological distress during lockdown following SARS-CoV-2 outbreak in type 1 diabetes. <i>Diabetes/Metabolism Research and Reviews</i> , 2021, 37, e3404.	1.7	19
20	Dysmetabolic adipose tissue in obesity: morphological and functional characteristics of adipose stem cells and mature adipocytes in healthy and unhealthy obese subjects. <i>Journal of Endocrinological Investigation</i> , 2021, 44, 921-941.	1.8	32
21	Management of patients with diabetes and obesity in the COVID-19 era: Experiences and learnings from South and East Europe, the Middle East, and Africa. <i>Diabetes Research and Clinical Practice</i> , 2021, 172, 108617.	1.1	31
22	Irisin and Incretin Hormones: Similarities, Differences, and Implications in Type 2 Diabetes and Obesity. <i>Biomolecules</i> , 2021, 11, 286.	1.8	20
23	Effects of Extra Virgin Olive Oil Polyphenols on Beta-Cell Function and Survival. <i>Plants</i> , 2021, 10, 286.	1.6	18
24	Report from the CVOT Summit 2020: new cardiovascular and renal outcomes. <i>Cardiovascular Diabetology</i> , 2021, 20, 75.	2.7	9
25	Lower risk of death and cardiovascular events in patients with diabetes initiating glucagon-like peptide-1 receptor agonists or sodium-glucose cotransporter-2 inhibitors: A real-world study in two Italian cohorts. <i>Diabetes, Obesity and Metabolism</i> , 2021, 23, 1484-1495.	2.2	20
26	Inhibition of Lysine 63 Ubiquitination Prevents the Progression of Renal Fibrosis in Diabetic DBA/2J Mice. <i>International Journal of Molecular Sciences</i> , 2021, 22, 5194.	1.8	4
27	Antineoplastic dosing in overweight and obese cancer patients: an Associazione Italiana Oncologia Medica (AIOM)/Associazione Medici Diabetologi (AMD)/Societ� Italiana Endocrinologia (SIE)/Societ� Italiana Farmacologia (SIF) multidisciplinary consensus position paper. <i>ESMO Open</i> , 2021, 6, 100153.	2.0	13
28	Postprandial glucose and HbA1c are associated with severity of obstructive sleep apnoea in non-diabetic obese subjects. <i>Journal of Endocrinological Investigation</i> , 2021, 44, 2741-2748.	1.8	5
29	Clinical Perspectives on the Use of Subcutaneous and Oral Formulations of Semaglutide. <i>Frontiers in Endocrinology</i> , 2021, 12, 645507.	1.5	28
30	Early prediction of pancreatic cancer from new-onset diabetes: an Associazione Italiana Oncologia Medica (AIOM)/Associazione Medici Diabetologi (AMD)/Societ� Italiana Endocrinologia (SIE)/Societ� Italiana Farmacologia (SIF) multidisciplinary consensus position paper. <i>ESMO Open</i> , 2021, 6, 100155.	2.0	20
31	<scp>S</scp>odium-glucose co-transporter-2 inhibitors and protection from cardiovascular death: Is it all about heart failure?. <i>Diabetes, Obesity and Metabolism</i> , 2021, 23, 2194-2196.	2.2	2
32	Role of Glucose-Lowering Medications in Erectile Dysfunction. <i>Journal of Clinical Medicine</i> , 2021, 10, 2501.	1.0	9
33	Impaired Leptin Signalling in Obesity: Is Leptin a New Thermolipokine?. <i>International Journal of Molecular Sciences</i> , 2021, 22, 6445.	1.8	21
34	Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial. <i>Lancet, The</i> , 2021, 398, 583-598.	6.3	274
35	Structured self-monitoring of blood glucose is associated with more appropriate therapeutic interventions than unstructured self-monitoring: A novel analysis of data from the PRISMA trial. <i>Diabetes Research and Clinical Practice</i> , 2021, 181, 109070.	1.1	9
36	Editorial: Reviews and Novel Clinical Perspectives on Semaglutide: A GLP-1 Receptor Agonist With Both Injectable and Oral Formulations. <i>Frontiers in Endocrinology</i> , 2021, 12, 760153.	1.5	1

#	ARTICLE	IF	CITATIONS
37	The European Association for the Study of Obesity (EASO) Endorses the Milan Charter on Urban Obesity. <i>Obesity Facts</i> , 2021, 14, 163-168.	1.6	5
38	Glycaemic target attainment in people with Type 2 diabetes treated with insulin glargine/lixisenatide fixed-ratio combination: a post hoc analysis of the LixiLan [®] O and LixiLan [®] L trials. <i>Diabetic Medicine</i> , 2020, 37, 256-266.	1.2	3
39	Efficacy of thermal ablation in benign non-functioning solid thyroid nodule: A systematic review and meta-analysis. <i>Endocrine</i> , 2020, 67, 35-43.	1.1	108
40	Reduced SIRT1 and SIRT2 expression promotes adipogenesis of human visceral adipose stem cells and associates with accumulation of visceral fat in human obesity. <i>International Journal of Obesity</i> , 2020, 44, 307-319.	1.6	48
41	Efficacy and safety of very low calorie ketogenic diet (VLCKD) in patients with overweight and obesity: A systematic review and meta-analysis. <i>Reviews in Endocrine and Metabolic Disorders</i> , 2020, 21, 5-16.	2.6	136
42	Performance of Five Ultrasound Risk Stratification Systems in Selecting Thyroid Nodules for FNA. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020, 105, 1659-1669.	1.8	105
43	Thermal ablation meta-analysis: the need of careful appraisal of meta-analysis methodology. <i>Endocrine</i> , 2020, 67, 270-271.	1.1	0
44	Similar glycaemic control and less hypoglycaemia during active titration after insulin initiation with glargine 300 units/mL and degludec 100 units/mL: A subanalysis of the BRIGHT study. <i>Diabetes, Obesity and Metabolism</i> , 2020, 22, 346-354.	2.2	6
45	Patient-reported outcomes in elderly patients with type 2 diabetes mellitus treated with dual oral therapy: a multicenter, observational study from Italy. <i>Current Medical Research and Opinion</i> , 2020, 36, 555-562.	0.9	1
46	Irisin increases the expression of anorexigenic and neurotrophic genes in mouse brain. <i>Diabetes/Metabolism Research and Reviews</i> , 2020, 36, e3238.	1.7	21
47	Differential indication for SGLT-2 inhibitors versus GLP-1 receptor agonists in patients with established atherosclerotic heart disease or at risk for congestive heart failure. <i>Metabolism: Clinical and Experimental</i> , 2020, 104, 154045.	1.5	23
48	The importance of the initial period of basal insulin titration in people with diabetes. <i>Diabetes, Obesity and Metabolism</i> , 2020, 22, 722-733.	2.2	24
49	Titrateable fixed-ratio combination of insulin glargine plus lixisenatide: A simplified approach to glycemic control in type 2 diabetes mellitus. <i>Diabetes Research and Clinical Practice</i> , 2020, 170, 108478.	1.1	14
50	Renoprotection with SGLT2 inhibitors in type 2 diabetes over a spectrum of cardiovascular and renal risk. <i>Cardiovascular Diabetology</i> , 2020, 19, 196.	2.7	52
51	Diabetes in the Time of COVID-19: A Twitter-Based Sentiment Analysis. <i>Journal of Diabetes Science and Technology</i> , 2020, 14, 1131-1132.	1.3	6
52	The Real-World Observational Prospective Study of Health Outcomes with Dulaglutide and Liraglutide in Type 2 Diabetes Patients (TROPHIÉS): Baseline Patient-Reported Outcomes. <i>Diabetes Therapy</i> , 2020, 11, 2383-2399.	1.2	5
53	<scpi>GlarLixi</scpi> effectively reduces residual hyperglycaemia in patients with type 2 diabetes on basal insulin: A post hoc analysis from the <scpi>LixiLan</scpi> study. <i>Diabetes, Obesity and Metabolism</i> , 2020, 22, 1683-1689.	2.2	11
54	The Role of Oxidative Stress in Cardiac Disease: From Physiological Response to Injury Factor. <i>Oxidative Medicine and Cellular Longevity</i> , 2020, 2020, 1-29.	1.9	149

#	ARTICLE	IF	CITATIONS
55	The diabetic lung: An easy target for <sc>SARSâ€CoV</sc>â€?. Diabetes/Metabolism Research and Reviews, 2020, 36, e3346.	1.7	11
56	Commentary: Glucose control: Not just a bystander in GLP-1RA-mediated cardiovascular protection. Metabolism: Clinical and Experimental, 2020, 109, 154272.	1.5	8
57	Efficacy and safety of flash glucose monitoring in patients with type 1 and type 2 diabetes: a systematic review and meta-analysis. BMJ Open Diabetes Research and Care, 2020, 8, e001092.	1.2	50
58	Functional loss of pancreatic islets in type 2 diabetes: How can we halt it?. Metabolism: Clinical and Experimental, 2020, 110, 154304.	1.5	25
59	Performance of contrast-enhanced ultrasound (CEUS) in assessing thyroid nodules: a systematic review and meta-analysis using histological standard of reference. Radiologia Medica, 2020, 125, 406-415.	4.7	48
60	Exercise and apulian hypocaloric diet affect adipokine changes and gastric banding-induced weight loss: A prospective study on severe obese subjects. Annals of Medicine and Surgery, 2020, 52, 10-15.	0.5	1
61	Cardiovascular protection with sodiumâ€glucose coâ€transporterâ€ inhibitors in type 2 diabetes: Does it apply to all patients?. Diabetes, Obesity and Metabolism, 2020, 22, 1481-1495.	2.2	17
62	Lipids and Glucose Metabolism. Trends in Andrology and Sexual Medicine, 2020, , 155-162.	0.1	0
63	Heterogeneity and Similarities in GLP-1 Receptor Agonist Cardiovascular Outcomes Trials. Trends in Endocrinology and Metabolism, 2019, 30, 578-589.	3.1	43
64	The Sentiment Analysis of Tweets as a New Tool to Measure Public Perception of Male Erectile and Ejaculatory Dysfunctions. Sexual Medicine, 2019, 7, 464-471.	0.9	16
65	Urinary miRNA-27b-3p and miRNA-1228-3p correlate with the progression of Kidney Fibrosis in Diabetic Nephropathy. Scientific Reports, 2019, 9, 11357.	1.6	75
66	Effect of onceâ€weekly dulaglutide versus insulin glargine in people with type 2 diabetes and different baseline glycaemic patterns: A post hoc analysis of the AWARDâ€ clinical trial. Diabetes, Obesity and Metabolism, 2019, 21, 2570-2575.	2.2	11
67	Effects of CPAP on Testosterone Levels in Patients With Obstructive Sleep Apnea: A Meta-Analysis Study. Frontiers in Endocrinology, 2019, 10, 551.	1.5	20
68	Achievement of glycaemic control is associated with improvements in lipid profile with iGlarLixi versus iGlar: A post hoc analysis of the LixiLanâ€ trial. Diabetes, Obesity and Metabolism, 2019, 21, 2712-2717.	2.2	8
69	Very-low-calorie ketogenic diet (VLCKD) in the management of metabolic diseases: systematic review and consensus statement from the Italian Society of Endocrinology (SIE). Journal of Endocrinological Investigation, 2019, 42, 1365-1386.	1.8	167
70	Glucose-lowering therapy and cardiovascular outcomes in patients with type 2 diabetes mellitus and acute coronary syndrome. Diabetes and Vascular Disease Research, 2019, 16, 399-414.	0.9	26
71	Insulin and Insulin Receptors in Adipose Tissue Development. International Journal of Molecular Sciences, 2019, 20, 759.	1.8	129
72	Insulin Glargine U100 Utilization in Patients with Type 2 Diabetes in an Italian Real-World Setting: A Retrospective Study. Journal of Diabetes Research, 2019, 2019, 1-10.	1.0	1

#	ARTICLE	IF	CITATIONS
73	Cover Image, Volume 21, Issue 12. Diabetes, Obesity and Metabolism, 2019, 21, i.	2.2	0
74	Efficacy and safety of GLP-1 receptor agonists as add-on to SGLT2 inhibitors in type 2 diabetes mellitus: A meta-analysis. Scientific Reports, 2019, 9, 19351.	1.6	43
75	Efficacy and safety of insulin glargine/lixisenatide (iGlarLixi) fixed-ratio combination in older adults with type 2 diabetes. Journal of Diabetes and Its Complications, 2019, 33, 236-242.	1.2	14
76	Italian consensus for the classification and reporting of thyroid cytology: the risk of malignancy between indeterminate lesions at low or high risk. A systematic review and meta-analysis. Endocrine, 2019, 63, 430-438.	1.1	36
77	<scp>GLP</scp>â€1 receptor agonist added to insulin versus basalâ€plus or basalâ€bolus insulin therapy in type 2 diabetes: A systematic review and metaâ€analysis. Diabetes/Metabolism Research and Reviews, 2019, 35, e3082.	1.7	57
78	Fine-needle aspiration to diagnose primary thyroid lymphomas: a systematic review and meta-analysis. European Journal of Endocrinology, 2019, 180, 177-187.	1.9	20
79	Primary hyperparathyroidism with surgical indication and negative or equivocal scintigraphy: safety and reliability of PTH washout. A systematic review and meta-analysis. European Journal of Endocrinology, 2019, 181, 245-253.	1.9	22
80	Treatment effects of once-weekly dulaglutide versus insulin glargine in patients with different baseline glycemic patterns (based on high/low fasting or high/low postprandial glucose): A post hoc analysis of the AWARD-2 clinical trial. , 2019, 14, .		0
81	HypoparaNet: A Database of Chronic Hypoparathyroidism Based on Expert Medical-Surgical Centers in Italy. Calcified Tissue International, 2018, 103, 151-163.	1.5	23
82	Diabetes and cancer: Pathophysiological fundamentals of a â€dangerous affairâ€™. Diabetes Research and Clinical Practice, 2018, 143, 378-388.	1.1	58
83	Metabolic control and complications in Italian people with diabetes treated with continuous subcutaneous insulin infusion. Nutrition, Metabolism and Cardiovascular Diseases, 2018, 28, 335-342.	1.1	8
84	Dietary intake and major food sources of polyphenols in people with type 2 diabetes: The TOSCA.IT Study. European Journal of Nutrition, 2018, 57, 679-688.	1.8	38
85	Gut: A key player in the pathogenesis of type 2 diabetes?. Critical Reviews in Food Science and Nutrition, 2018, 58, 1294-1309.	5.4	26
86	Oxidative stress and reactive oxygen species in endothelial dysfunction associated with cardiovascular and metabolic diseases. Vascular Pharmacology, 2018, 100, 1-19.	1.0	805
87	Effects of Structured Versus Unstructured Self-Monitoring of Blood Glucose on Glucose Control in Patients With Non-insulin-treated Type 2 Diabetes: A Meta-Analysis of Randomized Controlled Trials. Journal of Diabetes Science and Technology, 2018, 12, 183-189.	1.3	68
88	Effect of onceâ€weekly dulaglutide on glycated haemoglobin (<scp>HbA1c</scp>) and fasting blood glucose in patient subpopulations by gender, duration of diabetes and baseline <scp>HbA1c</scp>. Diabetes, Obesity and Metabolism, 2018, 20, 409-418.	2.2	56
89	Evaluation of the performance of Dutch Lipid Clinic Network score in an Italian FH population: The LIPIGEN study. Atherosclerosis, 2018, 277, 413-418.	0.4	48
90	Computerized Video-Capillaroscopy Alteration Related to Diabetes Mellitus and Its Complications. Advances in Experimental Medicine and Biology, 2018, 1072, 363-368.	0.8	16

#	ARTICLE	IF	CITATIONS
91	Deregulation of autophagy under hyperglycemic conditions is dependent on increased lysine 63 ubiquitination: a candidate mechanism in the progression of diabetic nephropathy. <i>Journal of Molecular Medicine</i> , 2018, 96, 645-659.	1.7	18
92	Propensity score-matched comparative analyses of simultaneously administered fixed-ratio insulin glargine 100%U and lixisenatide (iGlarLixi) vs sequential administration of insulin glargine and lixisenatide in uncontrolled type 2 diabetes. <i>Diabetes, Obesity and Metabolism</i> , 2018, 20, 2821-2829.	2.2	23
93	Efficacy of Vandetanib in Treating Locally Advanced or Metastatic Medullary Thyroid Carcinoma According to RECIST Criteria: A Systematic Review and Meta-Analysis. <i>Frontiers in Endocrinology</i> , 2018, 9, 224.	1.5	24
94	Serum Homocysteine Levels in Men with and without Erectile Dysfunction: A Systematic Review and Meta-Analysis. <i>International Journal of Endocrinology</i> , 2018, 2018, 1-7.	0.6	14
95	Adherence to antihyperglycemic medications and glucagon-like peptide 1-receptor agonists in type 2 diabetes: clinical consequences and strategies for improvement. <i>Patient Preference and Adherence</i> , 2018, Volume 12, 707-719.	0.8	52
96	Efficacy and safety of dapagliflozin in patients with type 2 diabetes and moderate renal impairment (chronic kidney disease stage 3A): The DERIVE Study. <i>Diabetes, Obesity and Metabolism</i> , 2018, 20, 2532-2540.	2.2	133
97	Pegvisomant in acromegaly: an update. <i>Journal of Endocrinological Investigation</i> , 2017, 40, 577-589.	1.8	53
98	A consensus statement for the clinical use of the renal sodium-glucose co-transporter-2 inhibitor dapagliflozin in patients with type 2 diabetes mellitus. <i>Expert Review of Clinical Pharmacology</i> , 2017, 10, 763-772.	1.3	14
99	Factors associated with improved glycemic control following continuous subcutaneous insulin infusion therapy in patients with type 2 diabetes uncontrolled with bolus-basal insulin regimens: analysis from the OpT2mise randomized trial. <i>Diabetes, Obesity and Metabolism</i> , 2017, 19, 1490-1494.	2.2	8
100	Familial hypercholesterolemia: The Italian Atherosclerosis Society Network (LIPIGEN). <i>Atherosclerosis Supplements</i> , 2017, 29, 11-16.	1.2	53
101	Spectrum of mutations in Italian patients with familial hypercholesterolemia: New results from the LIPIGEN study. <i>Atherosclerosis Supplements</i> , 2017, 29, 17-24.	1.2	65
102	Effects on the incidence of cardiovascular events of the addition of pioglitazone versus sulfonylureas in patients with type 2 diabetes inadequately controlled with metformin (TOSCA.IT): a randomised, multicentre trial. <i>Lancet Diabetes and Endocrinology</i> , 2017, 5, 887-897.	5.5	231
103	The Myokine Irisin Is Released in Response to Saturated Fatty Acids and Promotes Pancreatic β^2 -Cell Survival and Insulin Secretion. <i>Diabetes</i> , 2017, 66, 2849-2856.	0.3	96
104	GLP-1 Receptor Activation Inhibits Palmitate-Induced Apoptosis via Ceramide in Human Cardiac Progenitor Cells. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2017, 102, 4136-4147.	1.8	25
105	PKB/Akt and MAPK/ERK phosphorylation is highly induced by inositols: Novel potential insights in endothelial dysfunction in preeclampsia. <i>Pregnancy Hypertension</i> , 2017, 10, 107-112.	0.6	32
106	Lysine 63 ubiquitination is involved in the progression of tubular damage in diabetic nephropathy. <i>FASEB Journal</i> , 2017, 31, 308-319.	0.2	19
107	NANOG Plays a Hierarchical Role in the Transcription Network Regulating the Pluripotency and Plasticity of Adipose Tissue-Derived Stem Cells. <i>International Journal of Molecular Sciences</i> , 2017, 18, 1107.	1.8	22
108	Correction of intermittent hypoxia reduces inflammation in obese subjects with obstructive sleep apnea. <i>JCI Insight</i> , 2017, 2, .	2.3	58

#	ARTICLE	IF	CITATIONS
109	Glycated haemoglobin does not accurately predict average capillary glucose in non insulin-treated type 2 diabetes: The PRISMA study experience. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2016, 26, 169-170.	1.1	0
110	Long-Term Exposure of Pancreatic β -Cells to Palmitate Results in SREBP-1C-Dependent Decreases in GLP-1 Receptor Signaling via CREB and AKT and Insulin Secretory Response. <i>Endocrinology</i> , 2016, 157, 2243-2258.	1.4	22
111	Postprandial Glucagon Reductions Correlate to Reductions in Postprandial Glucose and Glycated Hemoglobin with Lixisenatide Treatment in Type 2 Diabetes Mellitus: A Post Hoc Analysis. <i>Diabetes Therapy</i> , 2016, 7, 583-590.	1.2	5
112	Treatment intensification in patients with inadequate glycemic control on basal insulin: rationale and clinical evidence for the use of short-acting and other glucagon-like peptide-1 receptor agonists. <i>Diabetes/Metabolism Research and Reviews</i> , 2016, 32, 497-511.	1.7	19
113	Efficacy and safety of dulaglutide in the treatment of type 2 diabetes: a comprehensive review of the dulaglutide clinical data focusing on the AWARD phase 3 clinical trial program. <i>Diabetes/Metabolism Research and Reviews</i> , 2016, 32, 776-790.	1.7	105
114	Glucose Control and Vascular Outcomes in Type 2 Diabetes: Is the Picture Clear?. <i>Diabetes Care</i> , 2016, 39, S187-S195.	4.3	42
115	The Burden of Structured Self-Monitoring of Blood Glucose on Diabetes-Specific Quality of Life and Locus of Control in Patients with Noninsulin-Treated Type 2 Diabetes: The PRISMA Study. <i>Diabetes Technology and Therapeutics</i> , 2016, 18, 421-428.	2.4	18
116	Italian Society for the Study of Diabetes (SID)/Italian Endocrinological Society (SIE) guidelines on the treatment of hyperglycemia in Cushing's syndrome and acromegaly. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2016, 26, 85-102.	1.1	9
117	Long-acting insulin analog detemir displays reduced effects on adipocyte differentiation of human subcutaneous and visceral adipose stem cells. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2016, 26, 333-344.	1.1	11
118	Italian Society for the Study of Diabetes (SID)/Italian Endocrinological Society (SIE) guidelines on the treatment of hyperglycemia in Cushing's syndrome and acromegaly. <i>Journal of Endocrinological Investigation</i> , 2016, 39, 235-255.	1.8	30
119	RAS/BRAF mutational status in familial non-medullary thyroid carcinomas: A retrospective study. <i>Oncology Letters</i> , 2015, 10, 1875-1881.	0.8	2
120	Influence of CAG Repeat Polymorphism on the Targets of Testosterone Action. <i>International Journal of Endocrinology</i> , 2015, 2015, 1-12.	0.6	62
121	The p66Shc protein controls redox signaling and oxidation-dependent DNA damage in human liver cells. <i>American Journal of Physiology - Renal Physiology</i> , 2015, 309, G826-G840.	1.6	18
122	Lipodystrophic Diabetes Mellitus: a Lesson for Other Forms of Diabetes?. <i>Current Diabetes Reports</i> , 2015, 15, 12.	1.7	7
123	The p66Shc redox adaptor protein is induced by saturated fatty acids and mediates lipotoxicity-induced apoptosis in pancreatic beta cells. <i>Diabetologia</i> , 2015, 58, 1260-1271.	2.9	40
124	Clusterin transcript variants expression in thyroid tumor: a potential marker of malignancy?. <i>BMC Cancer</i> , 2015, 15, 349.	1.1	14
125	Efficacy and Safety of Once-Weekly Dulaglutide Versus Insulin Glargine in Patients With Type 2 Diabetes on Metformin and Glimepiride (AWARD-2). <i>Diabetes Care</i> , 2015, 38, 2241-2249.	4.3	184
126	Rare diseases in clinical endocrinology: a taxonomic classification system. <i>Journal of Endocrinological Investigation</i> , 2015, 38, 193-259.	1.8	11

#	ARTICLE	IF	CITATIONS
127	GLP-1: benefits beyond pancreas. <i>Journal of Endocrinological Investigation</i> , 2014, 37, 1143-1153.	1.8	25
128	Association between Follicular Fluid Leptin and Serum Insulin Levels in Nonoverweight Women with Polycystic Ovary Syndrome. <i>BioMed Research International</i> , 2014, 2014, 1-7.	0.9	11
129	High GADA titer increases the risk of insulin requirement in LADA patients: a 7-year follow-up (NIRAD). <i>Tj ETQq1 1 0.784314 rgBT /Ove</i>	1.9	63
130	Distribution of cardiovascular disease and retinopathy in patients with type 2 diabetes according to different classification systems for chronic kidney disease: a cross-sectional analysis of the renal insufficiency and cardiovascular events (RIACE) Italian multicenter study. <i>Cardiovascular Diabetology</i> , 2014, 13, 59.	2.7	24
131	Treatment of Recent-Onset Type 1 Diabetic Patients With DiaPep277: Results of a Double-Blind, Placebo-Controlled, Randomized Phase 3 Trial. <i>Diabetes Care</i> , 2014, 37, 1392-1400.	4.3	52
132	Reductions in Post-Prandial Glucagon by the GLP-1 Receptor Agonist Lixisenatide Correlate to Reductions in PPG and A1C in Patients with Type 2 Diabetes Mellitus. <i>Canadian Journal of Diabetes</i> , 2014, 38, S11-S12.	0.4	0
133	Intensive glucose-lowering results in increased cardiovascular mortality in younger but not older individuals with type 2 diabetes. <i>Evidence-Based Medicine</i> , 2014, 19, 210-210.	0.6	0
134	Prospective, randomized trial on intensive SMBG management added value in non-insulin-treated T2DM patients (PRISMA): a study to determine the effect of a structured SMBG intervention. <i>Acta Diabetologica</i> , 2013, 50, 663-672.	1.2	22
135	Intensive Structured Self-Monitoring of Blood Glucose and Glycemic Control in Noninsulin-Treated Type 2 Diabetes. <i>Diabetes Care</i> , 2013, 36, 2887-2894.	4.3	98
136	Exendin-4 protects pancreatic beta cells from palmitate-induced apoptosis by interfering with GPR40 and the MKK4/7 stress kinase signalling pathway. <i>Diabetologia</i> , 2013, 56, 2456-2466.	2.9	59
137	Cardiovascular disease and glycemic control in type 2 diabetes: now that the dust is settling from large clinical trials. <i>Annals of the New York Academy of Sciences</i> , 2013, 1281, 36-50.	1.8	85
138	Pharmacologic agents for type 2 diabetes therapy and regulation of adipogenesis. <i>Archives of Physiology and Biochemistry</i> , 2013, 119, 139-150.	1.0	18
139	Effect of an L-Carnitine-Containing Peritoneal Dialysate on Insulin Sensitivity in Patients Treated With CAPD: A 4-Month, Prospective, Multicenter Randomized Trial. <i>American Journal of Kidney Diseases</i> , 2013, 62, 929-938.	2.1	42
140	The METABOLIC Study: Multidimensional assessment of health and functional status in older patients with type 2 diabetes taking oral antidiabetic treatment. <i>Diabetes and Metabolism</i> , 2013, 39, 236-243.	1.4	14
141	Therapeutic Efficacy of Lixisenatide Added to Basal Insulin is Greater When FPG is Well Controlled. <i>Canadian Journal of Diabetes</i> , 2013, 37, S31.	0.4	37
142	Elevated 1-Hour Postload Plasma Glucose Levels Identify Subjects With Normal Glucose Tolerance but Impaired β -Cell Function, Insulin Resistance, and Worse Cardiovascular Risk Profile: The GENFIEV Study. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2013, 98, 2100-2105.	1.8	92
143	Response to Comment on: Bosi et al. Intensive Structured Self-Monitoring of Blood Glucose and Glycemic Control in Noninsulin-Treated Type 2 Diabetes: The PRISMA Randomized Trial. <i>Diabetes Care</i> 2013;36:2887-2894. <i>Diabetes Care</i> , 2013, 36, e218-e218.	4.3	2
144	A master course on "Methodologies for Bio-Medical research in diabetes". <i>Archives of Physiology and Biochemistry</i> , 2013, 119, 137-138.	1.0	0

#	ARTICLE	IF	CITATIONS
145	Feasibility and Effectiveness in Clinical Practice of a Multifactorial Intervention for the Reduction of Cardiovascular Risk in Patients With Type 2 Diabetes. <i>Diabetes Care</i> , 2013, 36, 2566-2572.	4.3	20
146	Differences in Gene Expression and Cytokine Release Profiles Highlight the Heterogeneity of Distinct Subsets of Adipose Tissue-Derived Stem Cells in the Subcutaneous and Visceral Adipose Tissue in Humans. <i>PLoS ONE</i> , 2013, 8, e57892.	1.1	51
147	TNF α Signals via p66Shc to Induce E-Selectin, Promote Leukocyte Transmigration and Enhance Permeability in Human Endothelial Cells. <i>PLoS ONE</i> , 2013, 8, e81930.	1.1	29
148	Glucagon-Like Peptide-1 Counteracts Oxidative Stress-Dependent Apoptosis of Human Cardiac Progenitor Cells by Inhibiting the Activation of the c-Jun N-terminal Protein Kinase Signaling Pathway. <i>Endocrinology</i> , 2012, 153, 5770-5781.	1.4	31
149	Links between Metabolic Syndrome and Cardiovascular Autonomic Dysfunction. <i>Experimental Diabetes Research</i> , 2012, 2012, 1-9.	3.8	23
150	Corrigendum to "Adipose tissue, metabolic syndrome and polycystic ovary syndrome: from pathophysiology to treatment" [Reprod. Biomed. Online 19 (2009) 552-563]. <i>Reproductive BioMedicine Online</i> , 2012, 25, 335.	1.1	0
151	GnRH agonist versus GnRH antagonist in in vitro fertilization and embryo transfer (IVF/ET). <i>Reproductive Biology and Endocrinology</i> , 2012, 10, 26.	1.4	90
152	Human adipose tissue stem cells: relevance in the pathophysiology of obesity and metabolic diseases and therapeutic applications. <i>Expert Reviews in Molecular Medicine</i> , 2012, 14, e19.	1.6	30
153	Pathogenetic Mechanisms and Cardiovascular Risk. <i>Diabetes Care</i> , 2012, 35, 2607-2612.	4.3	36
154	The effects of weight loss due to gastric banding and lifestyle modification on red blood cell aggregation and deformability in severe obese subjects. <i>International Journal of Obesity</i> , 2012, 36, 342-347.	1.6	15
155	Interventional Therapy in Diabetic Foot: Risk Factors, Clinical Events and Prognosis at One Year Follow-up (A Study of 103 Cases). <i>Pakistan Journal of Biological Sciences</i> , 2012, 15, 789-794.	0.2	18
156	Oocyte morphological abnormalities in overweight women undergoing in vitro fertilization cycles. <i>Gynecological Endocrinology</i> , 2011, 27, 880-884.	0.7	51
157	Multifactorial intervention in Type 2 diabetes: The promise of incretin-based therapies. <i>Journal of Endocrinological Investigation</i> , 2011, 34, 69-77.	1.8	18
158	Insulin signaling in adipose tissue of patients with primary aldosteronism. <i>Journal of Endocrinological Investigation</i> , 2011, 34, 86-89.	1.8	5
159	p66Shc, a multifaceted protein linking Erk signalling, glucose metabolism, and oxidative stress. <i>Archives of Physiology and Biochemistry</i> , 2011, 117, 116-124.	1.0	33
160	Metabolic syndrome in subjects at high risk for type 2 diabetes: The genetic, physiopathology and evolution of type 2 diabetes (GENFIEV) study. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2011, 21, 699-705.	1.1	16
161	The Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation provides a better definition of cardiovascular burden associated with CKD than the Modification of Diet in Renal Disease (MDRD) Study formula in subjects with type 2 diabetes. <i>Atherosclerosis</i> , 2011, 218, 194-199.	0.4	55
162	Nateglinide provides tighter glycaemic control than glyburide in patients with Type 2 diabetes with prevalent postprandial hyperglycaemia. <i>Diabetic Medicine</i> , 2011, 28, 560-566.	1.2	9

#	ARTICLE	IF	CITATIONS
163	Wound Healing in Diabetes: Hemorheological and Microcirculatory Aspects. <i>Advances in Experimental Medicine and Biology</i> , 2011, 701, 263-269.	0.8	17
164	Clinical aggressiveness of incidental and non-incidental thyroid cancer. <i>Journal of Endocrinological Investigation</i> , 2011, 34, 599-603.	1.8	3
165	Increased carotid IMT in overweight and obese women affected by Hashimoto's thyroiditis: an adiposity and autoimmune linkage?. <i>BMC Cardiovascular Disorders</i> , 2010, 10, 22.	0.7	55
166	Association of <i>TCF7L2</i> gene variants with low GAD autoantibody titre in LADA subjects (NIRAD). <i>Journal of Endocrinology</i> , 2010, 163, 477-482.	1.2	47
167	Feasibility and effectiveness of a disease and care management model in the primary health care system for patients with heart failure and diabetes (Project Leonardo). <i>Vascular Health and Risk Management</i> , 2010, 6, 297.	1.0	235
168	Multiple endocrine neoplasia type 2 syndromes (MEN 2): results from the ItaMEN network analysis on the prevalence of different genotypes and phenotypes. <i>European Journal of Endocrinology</i> , 2010, 163, 963.	1.9	1
169	The GH/IGF1 axis and signaling pathways in the muscle and bone: mechanisms underlying age-related skeletal muscle wasting and osteoporosis. <i>Journal of Endocrinology</i> , 2010, 205, 201-210.	1.2	267
170	Zinc Transporter 8 Antibodies Complement GAD and IA-2 Antibodies in the Identification and Characterization of Adult-Onset Autoimmune Diabetes. <i>Diabetes Care</i> , 2010, 33, 104-108.	4.3	136
171	Multiple endocrine neoplasia type 2 syndromes (MEN 2): results from the ItaMEN network analysis on the prevalence of different genotypes and phenotypes. <i>European Journal of Endocrinology</i> , 2010, 163, 301-308.	1.9	111
172	Analysis of Insulin Sensitivity in Adipose Tissue of Patients with Primary Aldosteronism. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2010, 95, 4037-4042.	1.8	40
173	Exendin-4 Prevents c-Jun N-Terminal Protein Kinase Activation by Tumor Necrosis Factor- α and Inhibits TNF- α -Induced Apoptosis in Insulin-Secreting Cells. <i>Endocrinology</i> , 2010, 151, 2019-2029.	1.4	56
174	Use of isoxsuprine hydrochloride as a tocolytic agent in the treatment of preterm labour: a systematic review of previous literature. <i>Arzneimittelforschung</i> , 2010, 60, 415-420.	0.5	11
175	Role of UBC9 in the Regulation of the Adipogenic Program in 3T3-L1 Adipocytes. <i>Endocrinology</i> , 2010, 151, 5255-5266.	1.4	16
176	Different gene expression in human heart tissue and progenitor cells from control and diabetic subjects: relevance to the pathogenesis of human diabetic cardiomyopathy. <i>Surgical Technology International</i> , 2010, 19, 165-74.	0.1	2
177	Cross-Talk between PPAR γ and Insulin Signaling and Modulation of Insulin Sensitivity. <i>PPAR Research</i> , 2009, 2009, 1-12.	1.1	162
178	Adipose tissue function and dysfunction: organ cross talk and metabolic risk. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2009, 297, E975-E976.	1.8	11
179	Involvement of the p66 ^{Shc} protein in glucose transport regulation in skeletal muscle myoblasts. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2009, 296, E228-E237.	1.8	28
180	Human adipose tissue precursor cells: a new factor linking regulation of fat mass to obesity and type 2 diabetes?. <i>Archives of Physiology and Biochemistry</i> , 2009, 115, 218-226.	1.0	14

#	ARTICLE	IF	CITATIONS
181	Adipose tissue, metabolic syndrome and polycystic ovary syndrome: from pathophysiology to treatment. <i>Reproductive BioMedicine Online</i> , 2009, 19, 552-563.	1.1	67
182	Fat depot-related differences in gene expression, adiponectin secretion, and insulin action and signalling in human adipocytes differentiated in vitro from precursor stromal cells. <i>Diabetologia</i> , 2008, 51, 155-164.	2.9	125
183	Independent Influence of Insulin, Catecholamines, and Thyroid Hormones on Metabolic Syndrome. <i>Obesity</i> , 2008, 16, 2405-2411.	1.5	29
184	Abnormalities of Insulin-Like Growth Factor-I Signaling and Impaired Cell Proliferation in Osteoblasts from Subjects with Osteoporosis. <i>Endocrinology</i> , 2008, 149, 1302-1313.	1.4	46
185	Abnormalities of IGF-I signaling in the pathogenesis of diseases of the bone, brain, and fetoplacental unit in humans. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2008, 295, E991-E999.	1.8	45
186	Biological specificity of visceral adipose tissue and therapeutic intervention. <i>Archives of Physiology and Biochemistry</i> , 2008, 114, 277-286.	1.0	45
187	The IGF-I Signaling Pathway. <i>Current Pharmaceutical Design</i> , 2007, 13, 663-669.	0.9	263
188	Editorial [Hot Topic: Targeting the IGF-I Receptor Signaling Pathway: Implications for Human Cancer Therapy (Executive Editors: A. Ciampolillo and F. Giorgino)]. <i>Current Pharmaceutical Design</i> , 2007, 13, 661-662.	0.9	0
189	Exploiting the pleiotropic actions of GLP-1 for the management of type 2 diabetes mellitus and its complications. <i>Diabetes Research and Clinical Practice</i> , 2007, 78, S59-S67.	1.1	8
190	Expression and Secretion of the Atrial Natriuretic Peptide in Human Adipose Tissue and Preadipocytes*. <i>Obesity</i> , 2007, 15, 2181-2189.	1.5	19
191	GLP-1: a new approach for type 2 diabetes therapy. <i>Diabetes Research and Clinical Practice</i> , 2006, 74, S152-S155.	1.1	21
192	Insulin signalling in human adipose tissue. <i>Archives of Physiology and Biochemistry</i> , 2006, 112, 82-88.	1.0	33
193	Insulin Signaling in Human Visceral and Subcutaneous Adipose Tissue In Vivo. <i>Diabetes</i> , 2006, 55, 952-961.	0.3	83
194	Regional differences of insulin action in adipose tissue: insights from in vivo and in vitro studies. <i>Acta Physiologica Scandinavica</i> , 2005, 183, 13-30.	2.3	192
195	The IGF-I/IGF-I Receptor Pathway: Implications in the Pathophysiology of Thyroid Cancer. <i>Current Medicinal Chemistry</i> , 2005, 12, 2881-2891.	1.2	46
196	Reverse Transcriptase Inhibitors Down-Regulate Cell Proliferation in Vitro and in Vivo and Restore Thyrotropin Signaling and Iodine Uptake in Human Thyroid Anaplastic Carcinoma. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2005, 90, 5663-5671.	1.8	77
197	Intrauterine Growth Restriction in Humans Is Associated with Abnormalities in Placental Insulin-Like Growth Factor Signaling. <i>Endocrinology</i> , 2005, 146, 1498-1505.	1.4	138
198	A six month mitotane course induced sustained correction of hypercortisolism in a young woman with PPAD and Carney complex. <i>Journal of Endocrinological Investigation</i> , 2005, 28, 54-60.	1.8	8

#	ARTICLE	IF	CITATIONS
199	Pathophysiology of type 2 diabetes: Rationale for different oral antidiabetic treatment strategies. <i>Diabetes Research and Clinical Practice</i> , 2005, 68, S22-S29.	1.1	28
200	Dehydroepiandrosterone Stimulates Glucose Uptake in Human and Murine Adipocytes by Inducing GLUT1 and GLUT4 Translocation to the Plasma Membrane. <i>Diabetes</i> , 2004, 53, 41-52.	0.3	102
201	Role of the p66Shc Isoform in Insulin-like Growth Factor I Receptor Signaling through MEK/Erk and Regulation of Actin Cytoskeleton in Rat Myoblasts. <i>Journal of Biological Chemistry</i> , 2004, 279, 43900-43909.	1.6	41
202	Factors associated with progression to macroalbuminuria in microalbuminuric Type 1 diabetic patients: the EURODIAB Prospective Complications Study. <i>Diabetologia</i> , 2004, 47, 1020-8.	2.9	123
203	The ultrasound assessment of adipose tissue deposition in fetuses of "well controlled" insulin-dependent diabetic pregnancies. <i>Diabetic Medicine</i> , 2003, 20, 858-862.	1.2	22
204	Effect of Family History of Type 2 Diabetes on White Blood Cell Count in Adult Women. <i>Obesity</i> , 2003, 11, 1232-1237.	4.0	10
205	Vascular Risk Factors and Markers of Endothelial Function as Determinants of Inflammatory Markers in Type 1 Diabetes: The EURODIAB Prospective Complications Study. <i>Diabetes Care</i> , 2003, 26, 2165-2173.	4.3	199
206	Diagnostic Utility of Thyroglobulin Detection in Fine-Needle Aspiration of Cervical Cystic Metastatic Lymph Nodes from Papillary Thyroid Cancer with Negative Cytology. <i>Thyroid</i> , 2003, 13, 1163-1167.	2.4	135
207	Effect of Family History of Type 2 Diabetes on the Intima-Media Thickness of the Common Carotid Artery in Normal-Weight, Overweight, and Obese Glucose-Tolerant Young Adults. <i>Diabetes Care</i> , 2003, 26, 1230-1234.	4.3	95
208	Two Novel Proteins That Are Linked to Insulin-like Growth Factor (IGF-I) Receptors by the Grb10 Adapter and Modulate IGF-I Signaling. <i>Journal of Biological Chemistry</i> , 2003, 278, 31564-31573.	1.6	97
209	Timing of Fetal Growth Acceleration in Women with Insulin-Dependent Diabetes. <i>Fetal Diagnosis and Therapy</i> , 2003, 18, 437-441.	0.6	34
210	Continuous Subcutaneous Glucose Monitoring in Diabetic Patients: A multicenter analysis. <i>Diabetes Care</i> , 2002, 25, 347-352.	4.3	192
211	A family history of Type 2 diabetes is associated with increased plasma levels of C-reactive protein in non-smoking healthy adult women. <i>Diabetic Medicine</i> , 2002, 19, 689-692.	1.2	26
212	HGF and M-CSF modulate adhesion of MDA-231 breast cancer cell by increasing osteopontin secretion. <i>Journal of Biological Regulators and Homeostatic Agents</i> , 2002, 16, 190-5.	0.7	4
213	Relationship Between Plasma Sialic Acid Concentration and Microvascular and Macrovascular Complications in Type 1 Diabetes: The EURODIAB Complications Study. <i>Diabetes Care</i> , 2001, 24, 316-322.	4.3	54
214	Effects of Streptozocin Diabetes and Diabetes Treatment by Islet Transplantation on In Vivo Insulin Signaling in Rat Heart. <i>Diabetes</i> , 2001, 50, 2709-2720.	0.3	54
215	High Frequency of Incidental Diagnosis of Extrathyroidal Neoplastic Diseases at the Fine-Needle Aspiration Biopsy of Laterocervical Lymph Nodes in Patients with Thyroid Nodules. <i>Thyroid</i> , 2001, 11, 65-71.	2.4	14
216	The sentrin-conjugating enzyme mUbc9 interacts with GLUT4 and GLUT1 glucose transporters and regulates transporter levels in skeletal muscle cells. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2000, 97, 1125-1130.	3.3	156

#	ARTICLE	IF	CITATIONS
217	Reversal of foetal hydrops and foetal tachyarrhythmia associated with maternal diabetic coma. European Journal of Obstetrics, Gynecology and Reproductive Biology, 2000, 93, 33-35.	0.5	9
218	<i>In Vivo</i> Insulin Signaling in the Myocardium of Streptozotocin-Diabetic Rats: Opposite Effects of Diabetes on Insulin Stimulation of Glycogen Synthase and c-Fos ¹ . Endocrinology, 1999, 140, 1141-1150.	1.4	28
219	Islet transplantation restores normal levels of insulin receptor and substrate tyrosine phosphorylation and phosphatidylinositol 3-kinase activity in skeletal muscle and myocardium of streptozocin-induced diabetic rats. Diabetes, 1999, 48, 801-812.	0.3	23
220	Insulin-stimulated cell growth in insulin receptor substrate-1 ⁻ deficient ZR-75-1 cells is mediated by a phosphatidylinositol-3-kinase ⁻ independent pathway. , 1998, 70, 268-280.		26
221	Divergent Effects of Short ⁻ Term, Very ⁻ Low ⁻ Calorie Diet on Insulin ⁻ Like Growth Factor ⁻ and Insulin ⁻ Like Growth Factor Binding Protein ⁻ Serum Concentrations in Premenopausal Women with Obesity. Obesity, 1998, 6, 408-415.	4.0	17
222	Regulation of Insulin Signaling in the Skeletal and Cardiac Muscles of Diabetic Rats. , 1998, 14, 157-160.		0
223	Specific Increase in p85 [±] Expression in Response to Dexamethasone Is Associated with Inhibition of Insulin-like Growth Factor-I Stimulated Phosphatidylinositol 3-Kinase Activity in Cultured Muscle Cells. Journal of Biological Chemistry, 1997, 272, 7455-7463.	1.6	72
224	Lower androgenicity is associated with higher plasma levels of prothrombotic factors irrespective of age, obesity, body fat distribution, and related metabolic parameters in men. Metabolism: Clinical and Experimental, 1997, 46, 1287-1293.	1.5	71
225	Increase in both pro-thrombotic and anti-thrombotic factors in obese premenopausal women: relationship with body fat distribution. International Journal of Obesity, 1997, 21, 527-535.	1.6	84
226	Gender differences in serum leptin in obese people: relationships with testosterone, body fat distribution and insulin sensitivity. European Journal of Clinical Investigation, 1997, 27, 1016-1024.	1.7	103
227	INTERFERENCE OF ANGIOTENSIN-CONVERTING ENZYME INHIBITORS ON ERYTHROPOIESIS IN KIDNEY TRANSPLANT RECIPIENTS. Transplantation, 1997, 64, 913-918.	0.5	73
228	The adapter protein Grb10 associates preferentially with the insulin receptor as compared with the IGF-I receptor in mouse fibroblasts.. Journal of Clinical Investigation, 1997, 99, 830-837.	3.9	93
229	Interaction between the Grb10 SH2 Domain and the Insulin Receptor Carboxyl Terminus. Journal of Biological Chemistry, 1996, 271, 8882-8886.	1.6	99
230	Effects of contractile activity on tyrosine phosphoproteins and PI 3-kinase activity in rat skeletal muscle. American Journal of Physiology - Endocrinology and Metabolism, 1995, 268, E987-E995.	1.8	103
231	Insulin receptor phosphorylation, insulin receptor substrate-1 phosphorylation, and phosphatidylinositol 3-kinase activity are decreased in intact skeletal muscle strips from obese subjects.. Journal of Clinical Investigation, 1995, 95, 2195-2204.	3.9	457
232	Dexamethasone enhances insulin-like growth factor-I effects on skeletal muscle cell proliferation. Role of specific intracellular signaling pathways.. Journal of Clinical Investigation, 1995, 96, 1473-1483.	3.9	51
233	cDNA Cloning of the Rat IGF I Receptor: Structural Analysis of Rat and Human IGF I and Insulin Receptors Reveals Differences in Alternative Splicing and Receptor-Specific Domain Conservation. Biochemical and Biophysical Research Communications, 1994, 202, 1038-1046.	1.0	21
234	Relationship between insulin receptor tyrosine kinase activity and internalization in monocytes of non-insulin-dependent diabetes mellitus patients. Metabolism: Clinical and Experimental, 1993, 42, 882-887.	1.5	4

#	ARTICLE	IF	CITATIONS
235	Evidence for two insulin-like growth factor I receptors with distinct primary structure that are differentially expressed during development. <i>Regulatory Peptides</i> , 1993, 48, 279-290.	1.9	17
236	Relation between sex hormones and serum lipoprotein and lipoprotein(a) concentrations in premenopausal obese women.. <i>Arteriosclerosis and Thrombosis: A Journal of Vascular Biology</i> , 1993, 13, 675-679.	3.8	33
237	Glucocorticoid regulation of insulin receptor and substrate IRS-1 tyrosine phosphorylation in rat skeletal muscle in vivo.. <i>Journal of Clinical Investigation</i> , 1993, 91, 2020-2030.	3.9	160
238	Insulin-resistant MDA-MB231 human breast cancer cells contain a tyrosine kinase inhibiting activity. <i>Molecular Endocrinology</i> , 1993, 7, 1667-1676.	3.7	13
239	Changes in tyrosine phosphorylation of insulin receptors and a 170,000 molecular weight nonreceptor protein in vivo in skeletal muscle of streptozotocin-induced diabetic rats: effects of insulin and glucose.. <i>Endocrinology</i> , 1992, 130, 1433-1444.	1.4	54
240	Increased free testosterone but normal 5 α -reduced testosterone metabolites in obese premenopausal women. <i>Clinical Endocrinology</i> , 1992, 36, 553-558.	1.2	18
241	Changes in tyrosine phosphorylation of insulin receptors and a 170,000 molecular weight nonreceptor protein in vivo in skeletal muscle of streptozotocin-induced diabetic rats: effects of insulin and glucose. <i>Endocrinology</i> , 1992, 130, 1433-1444.	1.4	43
242	Insulin receptor expression and function in human breast cancer cell lines. <i>Cancer Research</i> , 1992, 52, 3924-30.	0.4	157
243	Low dehydroepiandrosterone circulating levels in premenopausal obese women with very high body mass index. <i>Metabolism: Clinical and Experimental</i> , 1991, 40, 187-190.	1.5	64
244	Overexpression of Insulin Receptors in Fibroblast and Ovary Cells Induces a Ligand-Mediated Transformed Phenotype. <i>Molecular Endocrinology</i> , 1991, 5, 452-459.	3.7	91